ArticleBMC infectious diseases2026
Prevalence and genotype distribution of human papillomavirus (HPV) in an at-risk and suspected population in Iran.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
- Factors associated with high-grade cervical dysplasia in colposcopy patients: the primary role of isolated HPV 16 positivity.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive cervical cancer is primarily caused by human papillomaviruses (HPV). In developing countries, HPV and viral hepatitis together are responsible for a quarter of all cancers. Valid regional data on the distribution of HPV types in men and women affected and unaffected by cervical cancer is vital for predicting the effectiveness of current vaccines and enhancing screening programs. This study was conducted to examine the prevalence and genotypes of HPV in suspected and at-risk populations of men and women in a center in Tehran.
methodsThis study was conducted from September 2023 to September 2024, during which 121 male and 93 female sexually active subjects were investigated to detect HPV and determine the high-risk and low-risk HPV strains. Pap smear samples were histologically examined, and then, HPV detection and genotype identification were performed using the INNO-LiPA HPV Genotyping Extra II Amp genotype via specific primers MY09 and MY11.
resultsOverall HPV prevalence was 28%, of which 43.4% of individuals were infected with high-risk HPV genotypes. The most common high-risk genotypes among both male and female subjects were HPV16 and HPV31. The remaining high-risk genotypes identified among infected women were HPV18, HPV35, HPV39, and HPV58, with a prevalence of 8.3% each. No significant differences were observed between men and women in the distribution of high-risk (χ²
conclusionThis study presents sex-disaggregated data on HPV genotype distribution and associated cytological abnormalities in an at-risk Iranian population. These findings inform vaccine policy, emphasize the importance of including men in prevention strategies, and, given the high prevalence of high-risk HPV vaccine strains observed, will improve forecasts of vaccine impact on cervical cancer and aid in developing enhanced screening procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.